



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Access to Health Care Policy

1 Purpose


To promote the management and development of access to health care, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereafter “Hengrui Pharma”, “the Company” or “We”) adheres to its mission and promise to “promote a healthier life for humankind through advancements in science”, and formulates this Policy in the pursuit of providing solution to global public health issues, and contribute to human health and wellbeing.

2 Scope

This Policy applies to the Company and its subsidiaries; we also encourage all relevant parties to act in line with this Policy.

3 Governance of Access to Health Care

At Hengrui Pharma, the Board of Directors has included access to health care issues in its management and decision-making process. The Strategy Committee, as a Board level representation, oversees the implementation of the Company’s access to health care initiatives. The Strategy Committee coordinates, assesses and evaluates the Company’s policies and strategic plans for access to health care. It also oversees the implementation of relevant policies and plans and regularly reports to the Board of Directors.





4 Compulsory Licensing and Fair Competition

Hengrui Pharma adheres to the provisions of the *Doha Declaration on the TRIPS Agreement and Public Health* on compulsory licensing of relevant medicines to safeguard the public's health. We strictly adhere to the provisions of the *Patent Law of the People's Republic of China* regarding compulsory licensing for drug patents in emergencies to safeguard public interests and health. Additionally, we support the entry of various generic drugs into the market to expand patients' treatment options, thereby continuously improving global health care affordability.

The Company sticks to its corporate responsibility of safeguarding global public health, and highly values medicine accessibility in special and emergency situations, such as issues related to medicine compulsory licensing and trade and imports. We will continue to work with our peers to contribute to policymaking on medicine compulsory licensing and imports at national level by proposing suggestions and other means, so as to better facilitate public health and/or public medication at present and in the future.

5 Equitable Pricing

At Hengrui Pharma, we prioritize making our products accessible and fairly priced in different regions. We are committed to carefully considering the economic and social differences among countries and regions, and analyzing regional gaps in terms of health care in the process of expansion into overseas market and implementing the principle of equitable pricing. Through these efforts, we ensure that our high-quality products are affordable in more markets.

5.1 Domestic Market

We continue to carry out price control on some products, vigorously support health insurance policies, actively participate in national health insurance negotiations, contribute to the construction of the national health insurance system, and offer patients more options for medication.

5.2 Overseas Market

In promoting our products to overseas market, we conduct thorough market and product research when establishing projects, and gather insights from local industry information to fully understand the prices of locally developed products in emerging markets and developing countries, the prices of local competitors, the local health care systems and the incomes of local residents. Based on this, we formulate differentiated product pricing strategies in an effort to guarantee fair and transparent pricing among different markets and ease the financial burden on patients in different regions.

In the future, the Company will gradually enhance the transparency of product pricing based on market feedback and characteristics in different regions, and endeavor to expand the scope of implementation of the fair pricing policy to all core products in all domestic and overseas markets, and thus continue to promote the transparency of product pricing and accessibility of



our medicines.

6 Innovative R&D

6.1 Antibiotic Resistance

Hengrui Pharma is fully aware of the potential risks to global public health posed by the problem of antibiotic resistance. To cope with this issue, we have set up a special R&D team to proactively initiate targeted R&D projects, striving to mitigate the risks of antibiotic resistance. We have established a series of projects on bacterial and fungal resistance to expedite the application of research results, in the pursuit of lowering the risk of antibiotic resistance and offering new solutions to the increasingly serious problem of antibiotic resistance.

6.2 Rare Diseases

The Company gives full play to its industry strengths and cooperates with its peers to actively engage in the clinical research of innovative drugs for rare diseases, focusing on a wide range of rare diseases in China and other countries, and endeavoring to address the unmet clinical needs globally.

7 Improving the Capacities of Developing Countries

The Company remains steadfast in its pursuit of improving and enhancing global public health across the world, including developing countries and regions. To ensure the stable operation of our overseas business, we act in strict accordance with local laws and regulations in different countries and regions. Additionally, we strive to continuously build up local drug supply chains, bolster the capacities of local health care workers, medical research capabilities and comprehensive medical services by cooperating with local partners, empowering our cooperation partners and launching training programs for health care workers.

Objectives for enhancing the capacities of developing countries:

- ✧ We will carry out medical research projects in developing countries or underdeveloped regions in the form of PPP (Public-Private Partnership) to fulfill our social responsibilities and facilitate the improvement of medical services in emerging markets.
- ✧ To guarantee drug safety for patients globally, we will fully leverage our resources and strengths in technologies, and assist developing countries and underdeveloped regions in bolstering pharmacovigilance capability. Before 2025, we will cooperate with our business partners to jointly build up pharmacovigilance capabilities that cover the whole lifecycle of drugs before, during and after the marketing process in at least 10 emerging markets.
- ✧ As of the end of 2023, our products have been marketed in over 45 developing countries/emerging markets. By 2026, at least 3 of our new products will be marketed in at least 3 additional developing countries/emerging markets compared to 2023.
- ✧ We place great emphasis on and identify material issues related to global health care, and will remain committed to capacity improvement in developing countries.
- ✧ We have initiated or supported a number of joint training programs, training programs and assistance programs for health care workers in the mainland of China. Going forward, we



will continue to launch training programs that cover more health care workers, thus contributing to the global endeavor to improve public health services.

8 Product Donation

The Company is devoted to satisfy the needs of patients, and tries every effort to supply medicines to different regions. We hold a longstanding commitment to improving the lives of patients with chronic diseases like high blood pressure, arthritis and diabetes, and have developed long-term drug donation plans for underdeveloped regions in China, with the goal of enhancing the well-being and mental and physical health of patients.

In the future, we plan to continue our donations in chronic disease management, and initiate targeted donation programs on chronic diseases like high blood pressure, diabetes and arthritis.

9 Availability and Revision

The Company reserves the right to revise, alter or repeal the Policy at any time for any reason. The Company will review this Policy regularly and revise it when necessary. The latest version of the Policy will be available on the official website of the Company: <https://www.hengrui.com/>.